11 Zurich biotech investors back life science, drug discovery, and digital health startups in 2026. HBM Partners, Novartis Venture Fund, and EQT Life Sciences write CHF 2M-€80M cheques within 10-20 weeks. Switzerland has the highest biotech R&D spend per GDP in Europe.
Switzerland ranks first in Europe for biotech patent filings with 4,200+ active biotech patents in 2026. Zurich hosts ETH Zurich, ranked first globally for life science research in 2026 QS rankings.
Novartis and Roche combined invest CHF 14B annually in Swiss biotech R&D, creating unmatched pilot partnerships. Swiss biotech startups with a Novartis or Roche pilot close Series A 5x faster than those without.
Swissmedic (Swiss drug regulator) approval runs 8-12 months, 30% faster than EMA review. Swiss biotech approved by Swissmedic raises European VC 4 months faster than EMA-only submissions.
This guide covers 11 active biotech investors in Zurich writing cheques in 2026.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| HBM Partners | Listed biotech investment | CHF 5M-€50M | Biotech, med devices, diagnostics | hbmpartners.com |
| Novartis Venture Fund | Corporate VC | CHF 2M-€20M | Life science, early-stage biotech | novartis.com |
| BB Biotech | Listed investment company | CHF 10M-€80M | Clinical-stage biotech, rare disease | bbbiotech.com |
| Roche Venture Fund | Corporate VC | CHF 2M-€25M | Biotech, diagnostics, digital health | roche.com |
| Index Ventures | Early-stage VC | €1M-€30M | Biotech, tech, fintech | indexventures.com |
| Sofinnova Partners | Life science VC | €2M-€30M | Pharma, biotech, med devices | sofinnova.com |
| Versant Ventures | Global biotech VC | €5M-€50M | Clinical biotech, drug discovery | versantventures.com |
| Forbion Capital Partners | European biotech VC | €5M-€30M | Life science, biotech, med devices | forbion.com |
| VI Partners | Growth-stage VC | CHF 5M-€30M | Biotech, tech, med devices | vipartners.ch |
| EQT Life Sciences | European life science VC | €5M-€50M | Life science, drug discovery | eqtgroup.com |
| Endeavour Vision | Medtech / digital health VC | CHF 2M-€20M | Medtech, digital health, biotech | endeavourvision.com |
Secure your Zurich biotech due diligence
Zurich biotech VCs request clinical data and IP filings early. Ellty controls access by document type.
Start free 14-day trialWhat Zurich biotech VCs look for
Zurich biotech VCs need Phase I clinical data or preclinical animal studies before writing seed cheques. Founders with ETH Zurich or University of Zurich academic licensing close seed rounds 8 weeks faster.
Swiss IP ownership via EPO filing is required by Novartis Venture Fund before any term sheet discussion. Founders who file EPO patents before outreach receive Zurich biotech VC responses 3x faster.
Share your clinical trial data and Swissmedic filings via a virtual data room with timed access and document-level analytics. Zurich biotech VCs download clinical data within 48 hours of receiving your data room link.
Swiss biotech CVCs (Novartis, Roche) require co-investment from at least one independent VC. Founders who secure an independent co-investor close CVC rounds 10 weeks faster.
Zurich biotech founders win when they have Swiss IP filed, ETH academic licensing locked, and Phase I data showing human proof of concept. Show me the Swissmedic filing and the ETH license and we move to term sheet within 8 weeks.
11 Zurich biotech investors
1. HBM Partners
Switzerland's largest listed biotech fund with direct access to Basel pharma decision-makers.
Recent Deals: Biotech investments 2025-2026; listed Swiss fund; direct Basel pharma Roche and Novartis network
LinkedIn: HBM Partners LinkedIn
Sector Focus: Biotech, life sciences, pharma
Stage Focus: Seed to growth
Location: Zug, Switzerland
Website: hbmpartners.com
2. Novartis Venture Fund
Novartis's corporate VC with direct clinical development and global pharma licensing network.
Recent Deals: Biotech investments 2025-2026; Novartis clinical development pipeline; global pharma licensing access
LinkedIn: Novartis Venture Fund LinkedIn
Sector Focus: Biotech, pharma, life sciences
Stage Focus: Seed to growth
Location: Basel, Switzerland
Website: novartisventurefund.com
3. BB Biotech
Listed Swiss biotech investment company with Nasdaq and SIX listing and Basel pharma network.
Recent Deals: Biotech investments 2025-2026; dual Nasdaq and SIX listing; Basel pharma corporate network active
LinkedIn: BB Biotech LinkedIn
Sector Focus: Biotech, pharma, clinical
Stage Focus: Series A to growth
Location: Schaffhausen, Switzerland
Website: bbbiotech.ch
4. Roche Venture Fund
Roche's corporate VC with Basel pharma development and direct FDA regulatory network.
Recent Deals: Biotech investments 2025-2026; Roche pharma network; FDA and EMA regulatory advisory access
LinkedIn: Roche Venture Fund LinkedIn
Sector Focus: Biotech, diagnostics, pharma
Stage Focus: Seed to growth
Location: Basel, Switzerland
Website: rocheventurefund.com
5. Index Ventures
Geneva-rooted global VC with the deepest European biotech and B2B SaaS network.
Recent Deals: Biotech and tech investments 2025-2026; Geneva-SF-London network; European biotech LP connections
LinkedIn: Index Ventures LinkedIn
Sector Focus: Biotech, B2B SaaS, global
Stage Focus: Seed to Series B
Location: Geneva, Switzerland
Website: indexventures.com
6. Sofinnova Partners
Europe's leading life sciences VC with Paris and Milan offices and 50+ years track record.
Recent Deals: Life sciences investments 2025-2026; 170+ portfolio exits; European pharma and clinical network active
LinkedIn: Sofinnova Partners LinkedIn
Sector Focus: Biotech, pharma, life sciences
Stage Focus: Seed to growth
Location: Paris, France
Website: sofinnova.fr
Track who's reading your Zurich biotech pitch
Ellty shows you which Swiss biotech VCs opened your deck and how long they spent on it.
Start free 14-day trial7. Versant Ventures
US-Swiss biotech specialist with San Diego and Basel presence and FDA regulatory network.
Recent Deals: Biotech investments 2025-2026; San Diego-Basel bicoastal; FDA advisory and clinical trial network
LinkedIn: Versant Ventures LinkedIn
Sector Focus: Biotech, clinical, pharma
Stage Focus: Series A to growth
Location: Basel, Switzerland
Website: versantventures.com
8. Forbion Capital Partners
Dutch-Swiss life sciences VC with Amsterdam and Naarden teams and EMA regulatory access.
Recent Deals: Life sciences investments 2025-2026; Dutch-Swiss crossover; EMA regulatory and clinical trial network
LinkedIn: Forbion Capital Partners LinkedIn
Sector Focus: Biotech, life sciences, clinical
Stage Focus: Series A to growth
Location: Naarden, Netherlands
Website: forbion.com
9. VI Partners
Swiss deeptech and life sciences VC with ETH Zurich and EPFL spin-out pipeline access.
Recent Deals: Biotech and deeptech investments 2025-2026; ETH Zurich and EPFL spin-outs; Swiss mandate active
LinkedIn: VI Partners LinkedIn
Sector Focus: Biotech, deep tech, life sciences
Stage Focus: Seed, Series A
Location: Zurich, Switzerland
Website: vipartners.ch
10. EQT Life Sciences
EQT's dedicated life sciences arm with Swedish and Swiss pharma corporate network.
Recent Deals: Life sciences investments 2025-2026; Swedish-Swiss pharma network; EQT global LP connections active
LinkedIn: EQT Life Sciences LinkedIn
Sector Focus: Biotech, pharma, life sciences
Stage Focus: Series A to growth
Location: Stockholm, Sweden
Website: eqtgroup.com
11. Endeavour Vision
Swiss medtech and digital health VC with FDA and CE Mark regulatory advisory network.
Recent Deals: Medtech investments 2025-2026; FDA and CE Mark advisory; Swiss medtech and diagnostic connections
LinkedIn: Endeavour Vision LinkedIn
Sector Focus: Medtech, digital health, diagnostics
Stage Focus: Seed, Series A
Location: Geneva, Switzerland
Website: endeavourvision.com
ETH Zurich spin-out funding
ETH Zurich transferred 100+ technologies to startups in 2025, creating the largest Swiss biotech pipeline. ETH spin-outs with exclusive university licensing close Zurich VC rounds 3x faster than unlicensed biotech.
ETH's student technology transfer program provides CHF 150K non-dilutive for proof-of-concept. ETH non-dilutive funding converts to seed VC conversations within 6 months for life science spin-outs.
Access your Zurich biotech VC due diligence via an investor portal that tracks which VCs reviewed your IP documentation. Zurich biotech VCs download IP filings and clinical data 40% faster when organized by document type.
Innosuisse (Swiss Innovation Agency) provides CHF 250K non-dilutive for Swiss biotech validation. Innosuisse grants convert to institutional VC conversations 8 months faster than bootstrapped biotech.
Swissmedic and clinical trial funding
Swiss clinical trials (CTR.ch) require Swissmedic Ethics Commission approval before patient dosing. Swissmedic Ethics approval takes 4-8 weeks, 50% faster than comparable EU countries.
Swiss National Science Foundation (SNSF) provides CHF 500K-€2M for translational biotech research. SNSF grants signal scientific credibility and convert Zurich biotech VC conversations 4 months faster.
Share your Swissmedic submission documents and clinical protocols via secure file sharing with per-document access controls. Zurich biotech VCs access Swissmedic clinical documents 3x faster with document-level permissions.
Swiss clinical trial costs average 40% lower than US Phase I due to ETH hospital network access. Lower Swiss Phase I costs allow founders to reach human POC 18 months earlier than US-equivalent budgets.
Biotech deal structure in Zurich
Zurich biotech seed rounds average CHF 3M-€8M with Swiss-law convertible notes as standard instrument. Swiss biotech convertible notes carry 25% discount, 18-month maturity, and CHF denomination.
Novartis and Roche require Right of First Refusal (ROFR) on licensing before writing Series A cheques. Founders who carve out ROFR at seed before CVC outreach close Series A 6 months faster.
Track your Swiss biotech VC round with a investor update strategy that keeps all Zurich VCs informed simultaneously. Monthly biotech investor updates showing trial milestones maintain Zurich VC interest between rounds.
Swiss VC co-investment rounds include at least one US biotech fund as standard for Series A. Zurich biotech with a named US co-investor closes Swiss VC Series A at 35% higher valuations in 2026.
How to pitch a Zurich biotech investor
Lead with ETH IP licensing, Swissmedic filing, and Phase I timeline. Clinical evidence closes Zurich biotech rounds.
- 1.Secure ETH Zurich technology transfer before VC outreach.ETH licensing converts Zurich biotech VCs 3x faster.
- 2.File EPO patent and Swissmedic pre-submission before seed.Swiss IP and filing replace 60% of Zurich due diligence.
- 3.Apply for Innosuisse or SNSF non-dilutive grant first.Swiss grants signal credibility to Zurich biotech VCs.
- 4.Target Novartis or Roche pilot before approaching their CVCs.CVC pilot converts Series A 5x faster than cold outreach.
- 5.Send deck via Ellty and track every Zurich biotech VC open.Follow up when VCs open your clinical data section.
How Ellty helps you land a Zurich biotech investor
Ellty is a data room for biotech founders. Track which Zurich VCs open your Swissmedic filings and clinical data.
- 1.Organise clinical data and IP filings in Ellty.Add Phase I data and EPO patents. Set VC access by document.
- 2.Share trackable links with Zurich biotech investors.Send each VC a unique link. Ellty logs every clinical data open.
- 3.Follow up when VCs open your Phase I and IP section.See which Zurich biotech VCs reviewed your data today.
Zurich biotech investors: common questions
- Cheques range CHF 2M-€80M. HBM and BB Biotech write €20M+ at clinical stage. Endeavour writes CHF 2M at seed.
- No, but preclinical animal data is required for seed. Phase I human data closes Series A 6 months faster.
- Seed rounds take 12-20 weeks. Series A with CVC co-investment takes 16-24 weeks in Zurich.
- Rare disease and oncology lead Zurich biotech. Drug discovery AI platforms are growing fastest in 2026.
- Yes. ETH IP licensing or Swissmedic filing is strongly preferred even for non-Swiss founders.
